ストックスクリーナーアプリを入手
74.11
2.70%
1.95
前日終値:
$72.16
開ける：
$72
24時間の取引高:
891.89K
Relative Volume:
1.65
時価総額：
$4.92B
収益：
-
当期純損益:
$-224.29M
株価収益率:
-19.00
EPS:
-3.9
ネットキャッシュフロー:
$-185.06M
1週間 パフォーマンス:
-4.69%
1か月 パフォーマンス:
-5.92%
6か月 パフォーマンス:
-13.50%
1年 パフォーマンス:
+5.51%
1日の値動き範囲:
$71.13
$74.38
1週間の範囲:
$71.13
$80.15
52週間の値動き範囲:
$55.53
$113.51
Nuvalent Inc Stock (NUVL) Company Profile
NUVL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
74.11 | 5.55B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-14 | アップグレード | UBS | Neutral → Buy |
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-10-24 | 開始されました | UBS | Neutral |
| 2024-08-29 | 開始されました | Barclays | Overweight |
| 2024-04-17 | 開始されました | Jefferies | Buy |
| 2024-04-01 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | 再開されました | Guggenheim | Buy |
| 2024-02-23 | 開始されました | Robert W. Baird | Outperform |
| 2023-09-27 | 開始されました | Stifel | Buy |
| 2023-08-08 | 開始されました | SVB Securities | Market Perform |
| 2023-07-24 | 開始されました | Guggenheim | Buy |
| 2023-01-18 | 開始されました | Wedbush | Outperform |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
すべてを表示
Nuvalent Inc (NUVL) 最新ニュース
Can Nuvalent Inc. navigate macro headwindsWeekly Investment Watchlist - sisain.net
Nuvalent Reports Q2 2025 Financials and Pipeline Progress - TipRanks
Nuvalent’s Promising Developments and Strong Financial Position Justify Buy Rating - TipRanks
Nuvalent’s Promising Drug Pipeline and Strategic Trials Drive Buy Rating - TipRanks
Nuvalent's Q2 Net Loss Widens - MarketScreener
Nuvalent's 2025 Momentum: Catalysts, Commercial Readiness, and Cash Runway Positioning for a Breakout Year - AInvest
Nuvalent (NUVL) Q2 R&D Up 65% - The Motley Fool
Nuvalent initiates rolling NDA submission for ROS1-positive NSCLC drug By Investing.com - Investing.com Australia
Earnings Flash (NUVL) Nuvalent Posts Q2 Net Loss Per Share $1.39, vs. FactSet Est of $1.22 - MarketScreener
Nuvalent initiates rolling NDA submission for ROS1-positive NSCLC drug - Investing.com
Nuvalent, Inc. SEC 10-Q Report - TradingView
Nuvalent's Dual Victory: FDA Rolling Review for ROS1 Cancer Drug While Phase 3 Trial Advances New ALK Treatment - Stock Titan
Analysts' Bullish Sentiments on Healthcare Companies: Avantor, Nuvalent, and Alphatec Holdings - AInvest
What catalysts could drive Nuvalent Inc. stock higher in 2025Build wealth faster with consistent growth stocks - Jammu Links News
What makes Nuvalent Inc. stock price move sharplyInvest confidently with professional market insights - Jammu Links News
Is Nuvalent Inc. a growth stock or a value stockExceptional financial outcomes - Jammu Links News
How volatile is Nuvalent Inc. stock compared to the marketInvest confidently with real-time data - Jammu Links News
What is the dividend policy of Nuvalent Inc. stockDynamic investment growth - Jammu Links News
How many analysts rate Nuvalent Inc. as a “Buy”Achieve breakthrough investment performance - Jammu Links News
What institutional investors are buying Nuvalent Inc. stockFind the best stocks for sustainable growth - Jammu Links News
What is the risk reward ratio of investing in Nuvalent Inc. stockGet ahead with breakthrough trading ideas - Jammu Links News
Published on: 2025-08-03 06:27:04 - Jammu Links News
Nuvalent’s Noci sells $321k in shares - Investing.com
Why is Nuvalent Inc. stock attracting strong analyst attentionBest Dividend Report From AI Tools - jammulinksnews.com
Nuvalent Inc. stock outlook for YEARTechnical Stock Breakout Predictions Signal Entry Points - metal.it
How Nuvalent Inc. stock performs during market volatilityWeekly Hot Picks With Buy Confidence Released - beatles.ru
Will Nuvalent Inc. Stock Benefit from AI and Green Energy TrendsFast Return Equity Trade Forecast Points to Small Caps - metal.it
Nuvalent Inc. Moves Into Overbought Range Analysts CautiousDay Trading Signals With High Precision Reviewed - metal.it
How high can Nuvalent Inc. stock price go in 2025AI Screening for Swing Trade Picks Finds Momentum - metal.it
Can Traders Expect Breakout From Nuvalent Inc. This WeekSmart Trade Plans With Risk Protection Explained - metal.it
Should I hold or sell Nuvalent Inc. stock in 2025Capitalize on market momentum for maximum gains - Jammu Links News
How does Nuvalent Inc. compare to its industry peersAchieve breakthrough profits with smart strategies - Jammu Links News
Nuvalent Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingHigh Return Potential - metal.it
What are Nuvalent Inc. company’s key revenue driversHigh-velocity capital appreciation - Jammu Links News
What are analysts’ price targets for Nuvalent Inc. in the next 12 monthsInvest confidently with proven investment plans - Jammu Links News
What markets is Nuvalent Inc. expanding into Is ISPO stock a good long term investment optionExceptional ROI - Jammu Links News
Nuvalent Inc (NUVL) 財務データ
収益
当期純利益
現金流量
EPS
0.24%
3.39%
大文字化:
|
ボリューム (24 時間):